Apis Capital Advisors LLC Purchases 266,000 Shares of Cellebrite DI Ltd. $CLBT

Apis Capital Advisors LLC increased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 77.3% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 610,000 shares of the company’s stock after buying an additional 266,000 shares during the period. Cellebrite DI accounts for approximately 2.5% of Apis Capital Advisors LLC’s portfolio, making the stock its 16th largest holding. Apis Capital Advisors LLC owned approximately 0.25% of Cellebrite DI worth $11,303,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in CLBT. Financial Management Professionals Inc. bought a new position in Cellebrite DI in the 3rd quarter worth about $28,000. CWM LLC raised its holdings in shares of Cellebrite DI by 85.7% in the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Cellebrite DI by 1,998.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,098 shares of the company’s stock valued at $34,000 after acquiring an additional 1,998 shares during the last quarter. Toth Financial Advisory Corp bought a new stake in shares of Cellebrite DI during the 3rd quarter valued at about $38,000. Finally, Pacer Advisors Inc. grew its holdings in shares of Cellebrite DI by 523.4% during the third quarter. Pacer Advisors Inc. now owns 2,743 shares of the company’s stock worth $51,000 after purchasing an additional 2,303 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Cellebrite DI Trading Down 0.6%

CLBT opened at $14.44 on Friday. Cellebrite DI Ltd. has a 12-month low of $11.76 and a 12-month high of $20.86. The stock has a 50-day moving average price of $15.27 and a 200-day moving average price of $16.91. The stock has a market capitalization of $3.60 billion, a P/E ratio of 46.58, a PEG ratio of 2.21 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm had revenue of $128.82 million for the quarter, compared to analysts’ expectations of $126.07 million. During the same period last year, the firm earned $0.10 earnings per share. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. On average, equities research analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.